Merck successful symposium on Niaspanor

Published: 2006-04-20 07:00:00

Updated: 2006-04-20 07:00:00

During the 5th Asia Pacific Society of Arteriosclerosis and Vascular Diseases (APSAVD) in Jeju island, Merck Korea took a symposium titled "Therapeutic Innovation in Atherogenic Dyslipidemia" at Tamla hall of Jeju International Convention Center on April 13.

Prof. John Chapman of National Heal...

Fees

- Email service daily and homepage access.

$300 per month. ($3,240 per year)
5 Email holders per each company.
Anual contract base.

Latest News

Which are outstanding tetravalent vaccines even for the young?

Disease treated the most with clinical trial drugs is respiratory disorder like lung cancer

Who will be the next Pharmaceutical Safety Bureau Director?

Celltrion completes clinical trials for Remsima SC for European approval

Sales listed pharmas made in the first half of the year

TOP

BACK